10. (Previously Presented) The formulation of claim 9, wherein said botulinum toxin Type B is present in a high molecular weight complex of 700 kilodaltons (kD) ± 10%.

11. (Previously Presented) The formulation of claim 9, wherein said botulinum toxin Type B is present at said therapeutic concentration between 1000-5000 U/ml.

12. (Currently Amended) The formulation of claim 8, wherein said botulinum toxin is botulinum toxin Type A, and is present in the stable ~~ready-to-use~~ liquid pharmaceutical formulation at said therapeutic concentration in the range of between 20-2000 U/ml.

13. (Currently Amended) The formulation of claim 12, wherein said botulinum toxin Type A is present in the stable~~, ready-to-use~~ liquid pharmaceutical formulation at said therapeutic concentration in the range of between 100-1000 U/ml.

14. (Currently Amended) The formulation of claim 1, wherein the stable~~, ready-to-use~~ liquid formulation comprises 100 mM sodium chloride; 10 mM succinate buffer at a buffered pH of 5.6; 0.5 mg/mL human serum albumin; and botulinum type B present at a concentration of 5,000 ± 1000 U/ml.

15. (Cancelled)

16. (Currently Amended) A stable~~, ready-to-use~~ liquid pharmaceutical formulation **for therapeutic use in humans** comprising

0.5 mg/ml human serum albumin,

botulinum toxin ~~formulation for therapeutic use in humans, comprising~~ **type B present at a concentration of 5,000 ± 1000 U/ml, and**

a pharmaceutically acceptable buffered saline which provides a buffered pH range to the formulation of pH 5.6, ~~and~~

wherein said botulinum toxin ~~that~~ is stable in said formulation~~; and~~ for at least about 6 months at a temperature between 10 and 30 degrees centigrade ± 10%, and